Evidence map›Paper›PMID 26365696›Full record

ArticleClinical biochemistry2016

Development and validation of an immunosensor for monocyte chemotactic protein 1 using a silicon photonic microring resonator biosensing platform.

Enrique Valera, Winnie W Shia, Ryan C Bailey

Abstract readValidation Study
In one paragraph

Article in Clinical biochemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. On-Chip Optical Detection of Viruses: A Review.Advanced photonics research · 2021
    Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Enrique ValeraDepartment of Chemistry, University of Illinois at Urbana - Champaign, 600 South Matthews Avenue, Urbana, IL 61801, United States.
Winnie W ShiaDepartment of Chemistry, University of Illinois at Urbana - Champaign, 600 South Matthews Avenue, Urbana, IL 61801, United States.
Ryan C BaileyDepartment of Chemistry, University of Illinois at Urbana - Champaign, 600 South Matthews Avenue, Urbana, IL 61801, United States. Electronic address: baileyrc@illinois.edu.
University of Illinois Urbana-Champaign · US

Funding

Meso-plex miRNA and protein profiling for cancer diagnostics using chip-integrateR33CA177462 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BAILEY, RYAN C, JOHNSON, MARK D · 2013 to 2015
$984k
NCI NIH HHS R33 CA177462NCI NIH HHS R33-CA177462-01
6 · The paper itself

Abstract

objectivesWe report the development of an optical immunosensor for the detection of monocyte chemotactic protein 1 (MCP-1) in serum samples. MCP-1 is a cytokine that is an emerging biomarker for several diseases/disorders, including ischemic cardiomyopathy, fibromyalgia, and some cancers. DESIGN AND

methodsThe detection of MCP-1 was achieved by performing a sandwich immunoassay on a silicon photonic microring resonator sensor platform. The resonance wavelengths supported by microring sensors are responsive to local changes in the environment accompanying biomarker binding. This technology offers a modularly multiplexable approach to detecting analyte localization in an antibody-antigen complex at the sensor surface.

resultsThe immunosensor allowed the rapid detection of MCP-1 in buffer and spiked human serum samples. An almost 2 order of magnitude linear range was observed, between 84.3 and 1582.1pg/mL and the limits of blank and detection were determined to be 0.3 and 0.5pg/mL, respectively. The platform's ability to analyze MCP-1 concentrations across a clinically-relevant concentration range was demonstrated.

conclusionsA silicon photonic immunosensor technology was applied to the detection of clinically-relevant concentrations of MCP-1. The performance of the sensor was validated through a broad dynamic range and across a number of suggested clinical cut-off values. Importantly, the intrinsic scalability and rapidity of the technology makes it readily amenable to the simultaneous detection of multiplexed biomarker panels, which is particularly needed for the clinical realization of inflammatory diagnostics.

Indexed as

Biosensing TechniquesBiomarkersChemokine CCL2FibromyalgiaHumansLimit of DetectionMyocardial IschemiaNeoplasmsPhotonsBiomarkersCCL2 protein, humanChemokine CCL2CytokineDiagnosticImmunoassayOptical biosensorSilicon photonics

Identifiers

PMID26365696
PMCPMC4715927
OpenAlexW1846223893

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.